Contents of volume 19

No. 1 (pp 1–90) published 12 February 1987
No. 2 (pp 91–182) published 10 April 1987
No. 3 (pp 183–272) published 6 May 1987
No. 4 (pp 273–350) published 6 July 1987

Abbolito MR → Pollera CF, et al. 257
Abramson HN → Banning JW, et al. 207
Adair CG, McElnay JC: The effect of dietary amino acids on the gastrointestinal absorption of melphalan and chlorambucil 343
Aherne GW → English J, et al. 287
Aherne GW → Khubieh J, et al. 175
Ahmed AE → Kretschmer NW, et al. 109
Ahmed AE, Grissom M, el-Azhary R, Haque A, Boor PJ, Costanzi J: Studies on the mechanism of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) -induced hepatotoxicity. II. Biochemical and morphological characterization of the injury and its prevention by phenobarbital 103
Ahmed R → Waxman JH, et al. 159
Ambrosini G → Amichetti M, et al. 87
Ameglio F → Pollera CF, et al. 257
Amichetti M, Piffer S, Valdagni R, Ambrosini G, Piazza M: Peripheral DTIC neurotoxicity: a case report 87
Andrews PA, Murphy MP, Howell SB: Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells 149
Antoniw P → Brindley CJ, et al. 221
Arendt J → English J, et al. 287
Arlin Z, Mehta R, Feldman E, Sullivan P, Pucillo A: Amsacrine treatment of patients with supraventricular arrhythmias and acute leukemia 163
Armentrout SA → Meador JM, et al. 177
Ashmun R → Roberts D, et al. 123
Atkins JN → Powell BL, et al. 250
Azarnia N → Preisler HD, et al. 69
el-Azhary R → Ahmed AE, et al. 103
el-Azhary RA → Kretschmer NW, et al. 109

Baker SR → Forastiere AA, et al. 155
Ballet F, Vrignaud P, Robert J, Rey C, Poupon R: Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated prefused rat liver 240
Balmer CE → Kuhn JG, et al. 133
Banham SW → Cummings J, et al. 296
Banning JW, Abramson HN, Wormser HC, WU J, Corbett TH: Relative cardiotoxicity and cytotoxicity of anthraquinonyl glucosaminosides 207
Barnett MJ, Rohatiner AZS, Ganesan TS, Richards MA, Miller A, Lister TA: A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults 169
Becker M → Muniz F, et al. 265
Bender JF → Kuhn JG, et al. 133
Bender JF → Muniz F, et al. 265
Bentley DP → Littlewood TJ, et al. 180
Berens ME → Saito T, et al. 233
Berens ME, Saito T, Welander CE, Modest EJ: Antitumor activity of new anthracycline analogues in combination with interferon alfa 301
Berger MR → Garzon FT, et al. 347
Besser GM → Waxman JH, et al. 159
Bhalla K, Grant S: Effect of deoxycytidine on the in vitro response of human leukemia cells to inhibitors of de novo pyrimidine biosynthesis 226
Bhat HB → Herman EH, et al. 277
Bishop JF → Reece PA, et al. 326
Boor PJ → Ahmed AE, et al. 103
Boor PJ → Kretschmer NW, et al. 109
Borsi JD, Revesz T, Schuler D: Prognostic importance of systemic clearance of methotrexate in childhood acute lymphoblastic leukemia 261
Brindley CJ, Pedley RB, Antoniw P, Newlands ES: Activity and distribution studies of etoposide and mitozolomide in vivo and in vitro against human choriocarcinoma cell lines 221
Buchanan RB → Mead GM, et al. 172

Camaggi CM → Pannuti F, et al. 311
Cano J-P → Payet B, et al. 319
Capizzi RL → Powell BL, et al. 250
Caponera ME → Powell BL, et al. 250
Carlini P → Pollera CF, et al. 335
Cashmore AR → Scanlon KJ, et al. 21
Cashmore AR → Scanlon KJ, et al. 25
Chakraborty J → Khubieh J, et al. 175
Chan TCK → Markman M, et al. 80
Christensen IJ → Roed H, et al. 16
Christensen IJ → Roed H, et al. 315
Cleary S → Markman M, et al. 80
Colls BM → Palmer MC 331
Comparsi R → Pannuti F, et al. 311
Corbett TH → Banning JW, et al. 207
Corbett T → O'Dwyer PJ, et al. 6
Costanzi J → Ahmed AE, et al. 103
Cradock → O'Dwyer PJ, et al. 6
Craig JB → Powell BL, et al. 250
Crowther D → Waxman JH, et al. 159
Cruz JM → Powell BL, et al. 250
Cummings J, Milroy R, Banham SW, Kaye SB: Method for the determination of 4-Demethoxydaunorubicin, its quinone and hydroquinone metabolites in human plasma and urine by high-performance liquid chromatography 296

Dean SW → Tew KD, et al. 291
Dodge RK → Goren MP, et al. 57
Dreyer RN → Scanlon KJ, et al. 21

Engelholm SA → Svendsen KR, et al. 118
English J, Aherne GW, Arendt J, Marks V: The effect of abolition of the endogenous corticosteroid rhythm on the circadian variation in methotrexate toxicity in the rat 287
Epirubicin Study Group for Hepatocellular Carcinoma: Intra-arterial administration of epirubicin in the treatment of Nonresectable hepatocellular carcinoma 183
Erlichman C, Soldin SJ, Thiessen JJ, Sturgeon JFG, Fine S: Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer 75

Fabre G → Payet B, et al. 319
Feldman E → Arlin Z, et al. 163
Ferrans VJ → Herman EH, et al. 277
Fine S → Erlichman C, et al. 75
Forastiere AA → Goren MP, et al. 57
Forastiere AA, Takasugi BJ, Baker SR, Wolf GT, Kudla-Hatch V: High-dose cisplatin in advanced head and neck cancer 155
Frederiksen S → Svendsen KR, et al. 118
Friche E, Skovsgaard T, Nissen NI: Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells 35
Fox BW → O'Connor PM 11

Gandara DR, George CB, Ries CA, Koretz MM, Lewis JP: Treatment of refractory chronic lymphocytic leukemia with prednimustine: A phase II study using strict response criteria 165
Ganesan TS → Barnett MJ, et al. 169

Garzon FT, Berger MR, Keppler BK, Schmähl D: Comparative antitumor activity of ruthenium derivatives with 5'-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats 347
George CB → Gandara DR, et al. 165
Gescher A → Newell D, et al. 91
Gibson NW → Tew KD, et al. 291
Giri SN → Robison TW 213
Goren MP, Forastiere AA, Wright RK, Horowitz ME, Dodge RK, Kamen BA, Viar MJ, Pratt CB: Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity 57
Grant S → Bhalla K 226
Gregory W → Waxman JH, et al. 159
Grieshaber C → O'Dwyer PJ, et al. 6
Griffin D, Said HM: The enterohepatic circulation of methotrexate in vivo: Inhibition by bile salt 40
Grillo-Lopez AJ → Kuhn JG, et al. 133
Grillo-Lopez AJ → Muniz F, et al. 265
Grissom M → Ahmed AE, et al. 103
Grosh WW → Wolff SN, et al. 246

Hagen B, Walseth F, Walstad RA, Iversen T, Nilsen OG: Single and repeated dose pharmacokinetics of thio-TEPA in patients treated for ovarian carcinoma 143
Hande KR → Wolff SN, et al. 246
Hansen HH → Roed H, et al. 16
Hansen HH → Roed H, et al. 315
Haque A → Ahmed AE, et al. 103
Harland S → Newell D, et al. 91
Herman EH, Ferrans VJ, Bhat HB, Witiak DT: Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159) 277
Herrod HG → Niell HB, et al. 47
Hillcoat BL → Reece PA, et al. 326
Hoff DD von → Kuhn JG, et al. 133
Hong W-S → Takahashi H, et al. 197
Horowitz ME → Goren MP, et al. 57
Hoshi A → Takahashi H, et al. 197
Hoth DF → O'Dwyer PJ, et al. 6
Howell A → Smith DB, et al. 138
Howell SB → Andrews PA, et al. 149
Howell SB → Kim S, et al. 307
Howell SB → Markman M, et al. 80
Hunter RF → Niell HB, et al. 47

Iigo M, Miwa M, Ishitsuka H, Nitta K: Potentiation of the chemotherapeutic action of 5'-deoxy-5-fluorouridine in combination with guanosine and related compounds 61
Ip M → Lam WK, et al. 269
Ishitsuka H → Iigo M, et al. 61
Israel M → Niell HB, et al. 47
Israel M → Sweatman TW 201
Iversen T → Hagen B, et al. 143

Jackson DV, Jr. → Powell BL, et al. 250
Jett JR → Takahashi H, et al. 197

Kamen BA → Goren MP, et al. 57
Kashani-Sabet M → Scanlon KJ, et al. 21
Kashani-Sabet M → Scanlon KJ, et al. 25
Kaye SB → Cummings J, et al. 296
Kaye SB → Kerr DJ 1
Kennedy BJ → Samuels BL, et al. 253
Keppler BK → Garzon FT, et al. 347
Kerpel-Fronius S → Verweij J, et al. 84
Kerr DJ, Kaye SB: Aspects of cytotoxic drug penetration, with particular reference to anthracyclines 1
Khubieh J, Aherne GW, Chakraborty J: Antibodies to 4-hydroxyandrostenedione – a new anti-breast cancer agent suitable for use in a radioimmunoassay 175
Kim DJ → Kim S, et al. 307
Kim S, Kim DJ, Howell SB: Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank liposomes 307
King SA → O'Dwyer PJ, et al. 6
Koretz MM → Gandara DR, et al. 165
Kretschmer NW, Boor PJ, el-Azhary RA, Ahmed AE, Reynolds ES: Studies on the mechanism of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) -induced hepatotoxicity. III. Ultrastructural characterization of bile duct injury 109
Kudla-Hatch V → Forastiere AA, et al. 155
Kuhn JG, Balmer CE, Ludden TM, Loesch DM, Hoff DD von, Bender JF, Grillo-Lopez AJ: Pharmacokinetics of ametantrone acetate (NSC-287513) 133
Kung TM → Lam WK, et al. 269

Lam WK, So SY, Kung TM, Sham MK, IP M: 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy in advanced adenocarcinoma of the lung: comparison of two dosage schedules 269
Lee T → Roberts D, et al. 123
Lewis JP → Gandara DR, et al. 165
Leyland-Jones B → O'Dwyer PJ, et al. 6
Lister TA → Barnett MJ, et al. 169
Lister TA → Waxman JH, et al. 159
Littlewood TJ, Bentley DP, McQueen INF: High dose etoposide does not cause peripheral neuropathy 180
Loesch DM → Kuhn JG, et al. 133
Loft H → Svendsen KR, et al. 118
Lucas SB → Smith DB, et al. 138
Ludden TM → Kuhn JG, et al. 133

Malpas JS → Waxman JH, et al. 159
Margison JM → Smith DB, et al. 138
Markman M, Chan TCK, Cleary S, Howell SB: Phase I trial of combination therapy of cancer with *N*-phosphonacetyl-L-aspartic acid and dipyridamole 80
Marks V → English J, et al. 287
Marolla P → Pollera CF, et al. 335
McElnay JC → Adair CG 343
McQueen INF → Littlewood TJ, et al. 180
Mead GM, Thompson J, Sweetenham JW, Buchanan RB, Whitehouse JMA, Williams CJ: Extensive stage small cell carcinoma of the bronchus. A randomised study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide 172
Meador JM, Armentrout SA, Slater LM: Third trimester chemotherapy and neonatal hematopoiesis 177
Mehta R → Arlin Z, et al. 163
Miller A → Barnett MJ, et al. 169
Milroy R → Cummings J, et al. 296
Miwa M → Iigo M, et al. 61
Mizukoshi O → Tachibana M, et al. 65
Modest EJ → Berens ME, et al. 301
Moroson BA → Scanlon KJ, et al. 21
Moroson BA → Scanlon KJ, et al. 25
Morstyn G → Reece PA, et al. 326
Muniz F, Vélez-Garcia E, Neidhart JA, Bender JF, Becker M, Grillo-Lopez AJ: A phase II trial of diaziquone in patients with head and neck cancer 265
Murphy MP → Andrews PA, et al. 149
Muss HB → Powell BL, et al. 250

Nakagawa K → Takahashi H, et al. 197
Nakano H → Takahashi H, et al. 197
Nardi M → Pollera CF, et al. 257
Nardi M → Pollera CF, et al. 335
Neidhart JA → Muniz F, et al. 265
Newell D, Gescher A, Harland S, Ross D, Rutty C: N-Methyl antitumour agents. A distinct class of anticancer drugs? 91
Newlands ES → Brindley CJ, et al. 221

Niell HB, Hunter RF, Herrod HG, Israel M: Effects of *N*-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines 47
Nilsen OG → Hagen B, et al. 143
Nishimura H → Tachibana M, et al. 65
Nissen NI → Friche E, et al. 35
Nitta K → Iigo M, et al. 61

O'Connor PM, Fox BW: Comparative studies of DNA cross-linking reactions following methylene dimethanesulphonate and its hydrolytic product, formaldehyde 11
O'Dwyer PJ, Shoemaker D, Zaharko S, Grieshaber C, Plowman J, Corbett T, Valeriote F, King SA, Cradock J, Hoth DF, Leyland-Jones B: Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent 6
Olver IN → Reece PA, et al. 326
Overgaard-Hansen K → Svendsen KR, et al. 118

Pallai M → Scanlon KJ, et al. 21
Pallai M → Scanlon KJ, et al. 25
Palmer MC, Colls BM: Amelioration of cytotoxic-induced emesis with high-dose metoclopramide, dexamethasone and lorazepam 331
Pannuti F, Camaggi CM, Strocchi E, Comparsi R: Medroxyprogesterone acetate plasma pharmacokinetics after intravenous administration in rabbits 311
Parganas E → Roberts D, et al. 123
Parracino C → Pollera CF, et al. 257
Payet B, Fabre G, Tubiana N, Cano J-P: Plasma kinetic study of folinic acid and 5-methyltetrahydrofolate in healthy volunteers and cancer patients by high-performance liquid chromatography 319
Pedley RB → Brindley CJ, et al. 221
Peroutka SJ: Chemotherapeutic agents do not interact with neurotransmitter receptors 131
Piazza M → Amichetti M, et al. 87
Piffer S → Amichetti M, et al. 87
Pinedo HM → Verweij J, et al. 84
Plowman J → O'Dwyer PJ, et al. 6
Pollera CF, Ameglio F, Reina S, Nardi M, Abbolito MR, Parracino C: Changes in serum iron levels following very high-dose cisplatin 257
Pollera CF, Nardi M, Marolla P, Carlini P: A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin 335
Poupon R → Ballet F, et al. 240
Powell BL, Muss HB, Capizzi RL, Caponera ME, White DR, Zekan PJ, Atkins JN, Jackson DV, Jr., Richards F, II, Craig JB, Cruz JM, Spurr CL: Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies 250
Prater K → Wolff SN, et al. 246
Pratt CB → Goren MP, et al. 57
Preisler HD, Rustum YM, Azarnia N, Priore R: Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside 69
Priore R → Preisler HD, et al. 69
Pucillo A → Arlin Z, et al. 163

Raffin TA → Yamauchi T, et al. 282
Reece PA, Bishop JF, Olver IN, Stafford I, Hillcoat BL, Morstyn G: Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small cell lung carcinoma 326
Rees LH → Waxman JH, et al. 159
Reina S → Pollera CF, et al. 257
Revesz T → Borsi JD, et al. 261
Rey C → Ballet F, et al. 240
Reynolds ES → Kretschmer NW, et al. 109
Richards F, II → Powell BL, et al. 250
Richards MA → Barnett MJ, et al. 169
Ries CA → Gandara DR, et al. 165
Robert J → Ballet F, et al. 240
Roberts D, Lee T, Parganas E, Wiggins L, Yalowich J, Ashmun R: Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells 123
Robison TW, Giri SN: Effects of chronic administration of doxorubicin on plasma levels of prostaglandins, thromboxane B_2, and fatty acids in rats 213
Roed H, Vindeløv LL, Christensen IJ, Spang-Thomsen M, Hansen HH: The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung 16
Roed H, Vindeløv LL, Spang-Thomsen M, Christensen IJ, Hansen HH: In vitro evaluation of a new nitrosourea, TCNU, against human small cell lung cancer cell lines 315
Rohatiner AZS → Barnett MJ, et al. 169
Romijn JC, Verkoelen CF, Splinter TAW: Problems of pharmacokinetic studies on alpha-difluoromethylornithine in mice 30
Ross D → Newell D, et al. 91
Rustum YM → Preisler HD, et al. 69
Rutty C → Newell D, et al. 91

Said HM → Griffin D 40
Saijo N → Takahashi H, et al. 197
Saito T → Berens ME, et al. 301
Saito T, Berens ME, Welander CE: Interferon-gamma and cytotoxic agents studied in combination using a soft agarose human tumor clonogenic assay 233
Saketos M → Scanlon KJ, et al. 21
Saketos M → Scanlon KJ, et al. 25
Sakurai M → Takahashi H, et al. 197
Samuels BL, Vogelzang NJ, Kennedy BJ: Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy 253
Sasaki Y → Takahashi H, et al. 197
Scanlon KJ, Cashmore AR, Kashani-Sabet M, Pallai M, Dreyer RN, Moroson BA, Saketos M: Inhibition of methionine uptake by methotrexate in mouse leukemia L1210 cells 21
Scanlon KJ, Kashani-Sabet M, Cashmore AR, Pallai M, Moroson BA, Saketos M: The role of methionine in methotrexate-sensitive and methotrexate-resistant mouse leukemia L1210 cells 25
Schmähl D → Garzon FT, et al. 347
Schrøder H: Methotrexate kinetics in myeloid bone marrow cells and peripheral neutrophils 42
Schrøder H: Methotrexate in neutrophils in children with acute lymphoblastic leukemia 339
Schuler D → Borsi JD, et al. 261
Shalet S → Waxman JH, et al. 159
Sham MK → Lam WK, et al. 269
Shoemaker D → O'Dwyer PJ, et al. 6
Sikic BI → Yamauchi T, et al. 282
Skovsgaard T → Friche E, et al. 35
Slater LM → Meador JM, et al. 177
Smith DB, Margison JM, Lucas SB, Wilkinson PM, Howell A: Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin 138
Smith D → Waxman JH, et al. 159
So SY → Lam WK, et al. 269
Soldin SJ → Erlichman C, et al. 75
Spang-Thomsen M → Roed H, et al. 16
Spang-Thomsen M → Roed H, et al. 315
Splinter TAW → Romijn JC, et al. 30
Spurr CL → Powell BL, et al. 250
Stafford I → Reece PA, et al. 326
Strocchi E → Pannuti F, et al. 311
Sturgeon JFG → Erlichman C, et al. 75
Stuurman M → Verweij J, et al. 84
Sullivan P → Arlin Z, et al. 163
Svendsen KR, Overgaard-Hansen K, Frederiksen S, Loft H, Engelholm SA: Studies on the mechanism of cytotoxicity of 3'-de-

oxyadenosine N^1-oxide in different strains of Ehrlich ascites tumor cells 118
Sweatman TW, Israel M: Comparative metabolism and elimination of adriamycin and 4'-epiadriamycin in the rat 201
Sweetenham JW → Mead GM, et al. 172

Tachibana M, Yasuda N, Yoshimatsu M, Nishimura H, Mizukoshi O: UFT for head and neck cancers: its tissue concentrations and effects on lymphocyte subpopulations 65
Takahashi H, Sasaki Y, Saijo N, Sakurai M, Nakano H, Nakagawa K, Hoshi A, Jett JR, Hong W-S: In vitro colony inhibition by carboplatin against stomach and lung cancer cell lines in comparison with cisplatin 197
Takasugi BJ → Forastiere AA, et al. 155
Tannock IF: Toxicity of 5-fluorouracil for aerobic and hypoxic cells in two murine tumours 53
Tew KD, Dean SW, Gibson NW: The effect of a novel taurine nitrosourea, 1-(2-chloroethyl)-3-[2-(dimethylaminosulfonyl)-ethyl]-1-nitrosourea (TCNU) on cytotoxicity, DNA cross-linking and glutathione reductase in lung carcinoma cell lines 291
Thiessen JJ → Erlichman C, et al. 75
Thompson J → Mead GM, et al. 172
Tsay B-L, Wolfinbarger L, Jr: Phase I study of *beta*-alanyl-melphalan as a potent anticancer drug 190
Tubiana N → Payet B, et al. 319

Valdagni R → Amichetti M, et al. 87
Valeriote F → O'Dwyer PJ, et al. 6
Vélez-Garcia E → Muniz F, et al. 265
Verkoelen CF → Romijn JC, et al. 30
Verweij J, Kerpel-Fronius S, Stuurman M, Vries de J, Pinedo HM: Absence of interaction between furosemide and mitomycin C 84
Viar MJ → Goren MP, et al. 57
Vindeløv LL → Roed H, et al. 16
Vindeløv LL → Roed H, et al. 315
Vogelzang NJ → Samuels BL, et al. 253
Vries de J → Verweij J, et al. 84
Vriesendorp HM, Vriesendorp R, Vriesendorp FJ: Prediction of normal tissue damage induced by cancer chemotherapy 273
Vriesendorp FJ → Vriesendorp HM, et al. 273
Vriesendorp R → Vriesendorp HM, et al. 273
Vrignaud P → Ballet F, et al. 240

Walseth F → Hagen B, et al. 143
Walstad RA → Hagen B, et al. 143
Waxman JH, Ahmed R, Smith D, Wrigley PFM, Gregory W, Shalet S, Crowther D, Rees LH, Besser GM, Malpas JS, Lister TA: Failure to preserve fertility in patients with Hodgkin's disease 159
Welander CE → Berens ME, et al. 301
Welander CE → Saito T, et al. 233
White DR → Powell BL, et al. 250
Whitehouse JMA → Mead GM, et al. 172
Wiggins L → Roberts D, et al. 123
Wilkinson PM → Smith DB, et al. 138
Williams CJ → Mead GM, et al. 172
Witiak DT → Herman EH, et al. 277
Wolf GT → Forastiere AA, et al. 155
Wolff SN, Grosh WW, Prater K, Hande KR: In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy 246
Wolfinbarger L, Jr → Tsay B-L 190
Wormser HC → Banning JW, et al. 207
Wright RK → Goren MP, et al. 57
Wrigley PFM → Waxman JH, et al. 159
Wu J → Banning JW, et al. 207

Yalowich J → Roberts D, et al. 123
Yamauchi T, Raffin TA, Yang P, Sikic BI: Differential protective effects of varying degrees of hypoxia on the cytotoxicities of etoposide and bleomycin 282
Yang P → Yamauchi T, et al. 282
Yasuda N → Tachibana M, et al. 65
Yoshimatsu M → Tachibana M, et al. 65

Zaharko S → O'Dwyer PJ, et al. 6
Zekan PJ → Powell BL, et al. 250